Immunic(US:IMUX) Prnewswireยท2025-05-02 10:30Core Insights - Immunic, Inc. is a biotechnology company focused on developing orally administered small molecule therapies for chronic inflammatory and autoimmune diseases [2][3] - The company is actively participating in several scientific and industry conferences in May 2025 to present its research and findings [1][2] Conference Participation - Immunic will present two abstracts at the Digestive Disease Week (DDW) from May 3-6, 2025, in San Diego, CA, focusing on its phase 1/1b clinical trial of IMU-856 for celiac disease [2] - A case study on clinical trial supply chain challenges in the Middle East and North Africa (MENA) will be presented at the Clinical Trial Supply Forum 2025 in Brussels, Belgium, from May 13-15, 2025 [2] - The company will also attend the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting 2025 in Phoenix, AZ, from May 28-31, 2025, where preclinical data on vidofludimus calcium (IMU-838) will be showcased [2] Product Development - The lead development program, vidofludimus calcium (IMU-838), is in phase 3 clinical trials for relapsing multiple sclerosis, with completion expected in 2026 [3] - IMU-856 targets SIRT6 to restore intestinal barrier function and has potential applications in various gastrointestinal diseases, including celiac disease and inflammatory bowel disease [3] - IMU-381 is a next-generation molecule currently in preclinical testing aimed at addressing gastrointestinal diseases [3]